Skip to main content

Abbisko of Shanghai Raises $70 Million for Novel Oncology-Immunocology Candidates

Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncology and immuno-oncology candidates. In the last year, Abbisko has started clinical trials of two internally discovered candidates after IND approvals in the US, China and Taiwan. It has also in-licensed two clinical stage assets, one from X4 Pharma and the other from AstraZeneca. More details.... Stock Symbol: (NYSE: AZN) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.